Eleven Biotherapeutics
Investor Relations Department
245 First Street, Suite 1800
Cambridge, MA 02142
United States

Visit IR website
Sign-up for email alerts

NASDAQ: EBIO	
Last Trade:	1.90
Trade Time:	4:00 PM ET April 28, 2017
Change:	-0.02 (1.042%)
Day Range	1.86 - 1.92
52-Week Range	0.72 - 5.97
Volume	254,881

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on our Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.

We have designed TPTs with the potential to offer:

• Multiple advantages in treating cancer over traditional antibody drug conjugates.

• Effective tumor targeting with cancer cell -killing... (more)

Stock Performance

Press Releases [View all]

April 28, 2017
Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017

April 2, 2017
Eleven Biotherapeutics Presents New Preclinical Data at AACR Supporting the Potential of the Company's Locally- and Systematically-Administered Drug Candidates

March 27, 2017
Eleven Biotherapeutics to Present New Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

March 24, 2017
Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

March 22, 2017
Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017

Upcoming Events [View all]

May 4, 2017 8:00 AM ET
Eleven Biotherapeutics First Quarter 2017 Results

Events [View all]

Financials [View all]

Fourth Quarter Financial Results

March 24, 2017
Annual Report (10-K)

April 7, 2017
Proxy Statement (DEF 14A)

November 14, 2016
Quarterly Report (10-Q)

August 12, 2016
Quarterly Report (10-Q)